Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07324577

Effectiveness of Virtual Reality (VR) in the Management of Anxiety for Patients Undergoing Radiotherapy

The purpose of this study is to evaluate the use and functionality of virtual reality (VR) during radiation therapy treatments for patients with prostate, breast, lung, or head and neck cancer.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Atrium Health Wake Forest Baptist Hayworth Cancer Center

High Point, North Carolina, 27262, United States

Location status: Recruiting

Location contact

Sheri Whittington

CONTACT

[email protected]

336-878-6107

Stephanie Parker, MS

PRINCIPAL_INVESTIGATOR

About this study

This is a randomized controlled trial that will assess the feasibility, acceptability, tolerability, and initial clinical efficacy of using a VR device during radiation therapy for participants with prostate cancer, breast cancer, lung cancer, or head and neck cancer.

Participants will be randomized 2:1 to either the VR device intervention arm or the standard of care control arm.

Participants will undergo pre-study assessments, assessments before and after the first radiation treatment, every 6th radiation treatment, and at the end of treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Patients:

Inclusion criteria

  • Participants planned for radiation therapy for 15 or more treatments with non-neutron generating energies (10 MV or less) per study PI for prostate, breast, lung, or head and neck cancer. Neutrons have the potential to damage the VR headset device and are generated for energies above 10 MV.
  • Age 18 years or older at the time of consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-33 or Karnofsky (KPS) 30-100 at the time of enrollment.
  • Ability to understand and the willingness to sign an IRB-approved informed consent document directly.

Exclusion criteria

  • Previous radiation therapy
  • VR device is determined to impede the radiation dosage during the VR device simulation and treatment planning
  • Participants with primary brain tumors, brain metastases, and cancer involving the sinuses, orbits, nose, or ears, are excluded from this clinical trial because the VR device may obstruct the area being treated
  • Participants with uncontrolled inter-current illness including but not limited to psychiatric illness/social situations that would limit compliance with study requirements per treating radiation oncologist.
  • Participants with known epilepsy, significant motion sickness, severe uncorrected visual impairment, severe uncorrected hearing impairment, or seizures, per participant report.
  • Participants with skin defects, infections, or open wounds in the area where the VR device is applied (face or scalp) or in the eyes per treating radiation oncologist.
  • Participants with pacemakers, internal defibrillators, hearing aid, or other implanted medical device. The Meta Quest device contains magnets and components that emit magnetic/electromagnetic fields which could affect the operation of nearby electronics and medical devices.

Radiation Therapists:

Inclusion criteria

  • Agreement to participate after reviewing the information sheet
  • Radiation therapist at AHWFBCCC High Point who has treated at least one participant who enrolled on to the study and used the VR device.

Treatment and study plan

Standard of care

Other

Radiation therapy for prostate cancer, breast cancer, lung cancer, or head and neck cancer.

Virtual Reality intervention

Other

Participants will wear the VR headset (Meta Quest 2) during standard of care radiation therapy

Radiation Therapist Survey

Other

Radiation therapists will be asked about their experiences and proficiency with using the VR device.

Primary outcomes

  1. VR Use During Treatment

    Time frame: Periprocedural (each treatment visit)

    A binary variable (Yes/No) will be created for participants at the level of individual treatment visit to signify whether the participants wore the VR device for the duration of their treatment.

  2. VR Functionality

    Time frame: Periprocedural (each treatment visit)

    VR device functionality (0-2) will be determined at the level of individual treatment visit using the following criteria as determined by the participant and/or treatment staff:

    0 = device not functional at any time during the treatment

    • = device functional for part but not all of the treatment duration
    • = device was functional for the duration of the treatment

Secondary outcomes

  1. Anxiety - Change over time

    Time frame: GAD-7: Baseline RTEQ: Periprocedural (After first and last treatment)

    Generalized Anxiety Disorder 7-item (GAD-7) to assess pre-existing generalized anxiety and the 23-item Radiotherapy Experience Questionnaire (RTEQ) situational unease and situational repose subscales.

  2. Acceptability of Implementing VR

    Time frame: At 36 months

    Radiation Therapist Survey (Administered to staff only)

Other outcomes

  1. Incidence of Treatment - Treatment Related Adverse Events

    Time frame: Periprocedural (each treatment visit)

    Total counts and grade of symptoms such as nausea, dizziness, seizures, blurred vision, fatigue, eye or muscle twitching, instability in posture, blackouts triggered by light flashes or patterns, and headache.

  2. Anxiety - Change over the course of treatment

    Time frame: Periprocedural (first treatment, last treatment, weekly during treatment)

    Single Item Anxiety Questionnaire

  3. Anxiety - Change over the course of treatment

    Time frame: Periprocedural (first treatment, last treatment, weekly during treatment)

    Anxiety evaluation with heart rate

  4. Participant Satisfaction

    Time frame: 4-6 weeks following randomization

    VR Satisfaction Questionnaire

Study contacts

Contact information is provided by the study sponsor or research team.

Sheri Whittington

CONTACT

[email protected]

336-878-6107

Sponsors and collaborators

Lead sponsor

Wake Forest University Health Sciences

Other

Collaborators

  • Atrium Health Wake Forest Baptist
  • National Cancer Institute (NCI)

Registry information

Official study title

Effectiveness of Virtual Reality in the Management of Anxiety for Patients Undergoing Radiotherapy

Acronym: RELAX

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Jan 7, 2026
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.